Should I buy AbbVie stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring AbbVie's performance for more than three years. Every month, hundreds of thousands of users across Canada rely on us to analyze market trends and highlight the best investment opportunities. Our reports are intended for informational purposes only and should not be considered investment advice. In line with our ethical guidelines, we have never been, and will never be, compensated by AbbVie.

What is AbbVie?

How much is AbbVie stock?

The price of AbbVie stock is declining this week. As of April 30, 2025, ABBV shares are trading at $193.05 USD, down 0.24% in the past 24 hours and showing an 8.48% decrease over the last week. The company holds a market capitalization of $341.49 billion, with an average 3-month daily volume of 7.67 million shares. AbbVie’s P/E ratio is 82.50, offering a dividend yield of 3.39%, and its beta of 0.54 reflects lower volatility than the broader market. The recent dip may interest Canadian investors seeking long-term income opportunities in a relatively stable healthcare leader.

Our full analysis on AbbVie stock

After a thorough review of AbbVie’s most recent quarterly results, coupled with an analysis of the stock’s robust performance over the past three years, we applied our proprietary algorithms to synthesize a range of data: from advanced technical indicators and market sentiment, to fundamental sector drivers and peer benchmarking. The outcome highlights a dynamic and evolving investment proposition. So, why might AbbVie stock once again become a strategic entry point into the global healthcare and pharmaceuticals sector as we look toward 2025?

Recent Performance and Market Context

AbbVie (NYSE: ABBV) has demonstrated marked resilience and growth amid evolving market conditions. Over the past year, the stock has appreciated by +18.7%, significantly outperforming the broader S&P 500 Healthcare index, and even after a modest 4.2% retreat over the prior six months, the longer-term trend underscores its defensive appeal. The recent weekly pullback of -8.5%—driven largely by sector rotation and profit taking after approaching its 52-week high of $218.66—has provided a timely reset, bringing the share price to a current $193.05 (as of April 30, 2025).

Notably, AbbVie’s latest Q1 results shattered expectations with revenues up 8.4% year-over-year. This solid operational performance catalyzed a positive revision in EPS guidance for 2025, fueling investor confidence at a time when blue-chip defensiveness remains in high demand. Macroeconomic uncertainty—including ongoing inflationary pressures and geopolitical risk—has notably increased market interest in companies with differentiated R&D, yield support, and pricing power. Within this context, AbbVie is strategically positioned, given its track record of transforming R&D investment into commercial pipeline success—thereby insulating shareholders from cyclical headwinds.

Bullish sentiment has also been supported by broader healthcare industry tailwinds. Demographic trends—such as population aging across North America and Europe—are fueling sustained demand in chronic disease management, immunology, neuroscience, and oncology. As Canadian investors seek diversification beyond the domestic market, large-cap U.S. drug manufacturers like AbbVie are attracting renewed attention for their stability and income generation potential.

Technical Analysis

From a technical perspective, AbbVie currently exhibits strong bullish momentum supported by multiple timeframes and indicator convergence. The price structure is firmly established above the 20-day ($184.94), 50-day ($189.26), 100-day ($187.92), and 200-day ($185.26) moving averages. This alignment reflects cohesive market accumulation and points to a constructive, longer-term price uptrend.

• RSI (14-day) at 63.52 signals the stock is neither overbought nor oversold, suggesting fresh capital inflow can be absorbed without technical excess.
• MACD (12,26,9) at 2.68 is in clear positive territory and trending upward, historically a precursor to further price appreciation.
• Support levels near $188.94 and $185.55 have repeatedly held during intraday pullbacks, signifying robust investor conviction at these ranges.
• Resistance levels at $194.43 and $196.52 define the next zones for a potential breakout, with the recent pullback increasing the likelihood of a bullish reversal.

Weekly momentum remains favourable, especially considering the strong “buy” consensus seen across popular technical platforms. The confluence of positive momentum with support at major technical levels increases the probability that AbbVie is in the early stages of a renewed advance—precisely the conditions astute investors monitor for strategic entry points.

Fundamental Analysis

On fundamental grounds, AbbVie stands out as a leader in both growth orientation and dividend stability. Q1 2025 revenues reached $13.34 billion (+8.4% year-on-year), with adjusted EPS advancing +6.5% to $2.46. Critically, operational excellence has translated into a formidable adjusted operating margin of 42.3%, allowing AbbVie to sustain both R&D investment and a compelling dividend yield of 3.39% ($6.56 annualized payout).

A deeper dive shows that core growth is increasingly driven by the immunology portfolio:

• Skyrizi and Rinvoq revenues soared by 70.5% and 57.2% year-on-year, respectively, more than compensating for the anticipated decline in legacy Humira sales (down 50.6% as biosimilars gain share).
• The emerging neuroscience portfolio (+16.1% YoY) has demonstrated consistent volume gains, most notably in Vraylar and Botox Therapeutic.
• Oncology remains resilient; while Imbruvica declined, Venclexta is gaining ground, and notable progress is being made in the late-stage pipeline.

On valuation, the headline P/E ratio of 82.5 reflects adjustments related to asset write-downs, litigation settlements, and amortization typical of the pharmaceutical sector. When assessed using forward P/E ratios and complemented by strong operational metrics (robust top-line growth, high-margin product mix, strong free cash flow), AbbVie’s premium is justified by the defensive, high-visibility earnings profile and the potential embedded in its innovation pipeline.

Finally, AbbVie’s brand recognition, global franchise, and culture of R&D excellence create significant competitive barriers. The company’s track record in commercializing both organic and licensed assets solidifies its structural strengths and positions it for sustained share gains in high-value indications.

Volume and Liquidity

Trading liquidity remains a critical consideration—particularly for institutional investors and active traders. Average daily volume stands at 7.67 million shares, underscoring deep secondary-market liquidity and tight bid-ask spreads. This supports both accumulation and tactical trading strategies, insulating participants from undue impact costs or illiquidity discounts.

AbbVie’s substantial float and market capitalization of $341.49 billion situate it solidly within the elite mega-cap cohort, contributing to dynamic valuation and robust representation within major index funds. This breadth of market participation is often a validation of confidence, as sustained investor interest drives more reliable price discovery and resilience to episodic volatility.

Catalysts and Positive Outlook

Several imminent and longer-term catalysts reinforce AbbVie’s positive risk/reward profile:

• Product Pipeline and Approvals: Multiple regulatory wins reinforce medium-term visibility. Notably, the European Commission’s approval for Rinvoq in giant cell arteritis, alongside the FDA greenlight for Emblaveo, signal near-term revenue expansion.
• Strategic Collaborations and M&A: The partnership with Xilio Therapeutics amplifies the company’s immunotherapy ambitions, while the obesity franchise collaboration with Gubra opens major new addressable markets.
• Pipeline Maturation: Submission of trenibotulinumtoxinE for aesthetic use, and compelling Phase 3 data for Elahere (targeting advanced ovarian cancer), showcase the breadth and clinical momentum in late-stage R&D.
• Leadership and Governance: The elevation of Robert A. Michael to CEO and chairman underscores management continuity and strategic development, sustaining stakeholder confidence.
• ESG and Sustainability: AbbVie continues to reinforce commitments to responsible stewardship—across supply chains, patient access, and broader social impact—which is increasingly valued by institutional and retail investors alike.
• Macro Tailwinds: Healthcare expenditure, demographic aging, and greater prevalence of chronic disease drive secular demand for innovative and proven therapies—a context in which AbbVie is both a leader and early mover.

With the backdrop of these catalysts, the company’s EPS guidance raise for 2025 reflects not just operational outperformance, but confidence in sustaining above-industry growth over the medium term.

Investment Strategies

Current conditions offer compelling arguments for a variety of entry approaches tailor-made to investor profiles:

• Short-Term Positioning:
• Strategic entry around current support levels ($188.94–$193.05) may allow traders to capture the expected bounce toward resistance at $194.43 and $196.52.
• Volume contraction coupled with stabilization in RSI suggests dry powder for buyers; bullish divergence in MACD is a technical trigger to watch.
• Medium-Term Accumulation:
• Investors with a 6–12 month horizon could capitalize on the post-earnings price retracement, positioning ahead of anticipated product launches and further regulatory decisions.
• Dividend growth and ‘quality premium’ characteristics make AbbVie a stand-out amidst potential economic softening.
• Long-Term Allocation:
• For those targeting multi-year capital appreciation and income, AbbVie’s diversified portfolio and robust pipeline offer attractive asymmetry between risk and reward.
• The recent management transition, coupled with aggressive expansion in neuroscience and obesity, open new secular growth drivers that are largely unpriced by consensus.

In all scenarios, layering into positions at current technical lows, or on confirmation of reversal toward resistance, seems supported by both technical and fundamental read-throughs.

Is It the Right Time to Buy AbbVie?

AbbVie exhibits a compelling combination of dynamic growth, sustainability, and yield—the hallmarks of a standout healthcare investment. Its diversified product base has demonstrated resilience by not only absorbing industry headwinds (such as the Humira patent cliff and fluctuations in aesthetics) but also by powering through with impressive pipeline delivery and operational execution. The stock’s defensive qualities, anchored by a strong dividend and active capital management, are particularly relevant given the evolving macro landscape.

While the absolute valuation remains elevated, AbbVie’s enterprise value is amply justified by its durable cash flows, innovation-led differentiation, and ability to redeploy capital towards both organic growth and accretive external partnerships. The recent pullback from historical highs, coupled with robust technical indicators and a swathe of near-term catalysts, seems to represent an excellent window for renewed investor engagement.

For Canadian investors seeking exposure to a sector with enduring global demand, high barriers to entry, and a proven leadership pedigree, AbbVie may well be entering a new bullish phase. Its forward-looking EPS guidance, consistent dividend growth, and R&D momentum all contribute to a positive risk-reward calculus that justifies serious consideration for both growth and income-oriented portfolios.

In sum, AbbVie’s alignment of technical resilience, fundamental strength, and visible catalysts suggests it is increasingly well-positioned for sustained outperformance as 2025 unfolds. For investors prepared to capitalize on world-class healthcare innovation—at a moment of temporary price consolidation—AbbVie appears to offer a strategic opportunity worthy of close attention and confidence.

How to buy AbbVie stock in Canada?

Buying AbbVie stock online is straightforward and secure when you go through a regulated Canadian broker. Investors can choose between two main methods: purchasing actual AbbVie shares (spot buying) or trading AbbVie Contracts for Difference (CFDs), which allow you to speculate on price movements without owning the underlying shares. Both approaches offer flexibility for different investor profiles and risk appetites. Below, you’ll find a detailed comparison of these methods, followed by a broker comparison further down the page so you can find the platform best suited to your needs.

Cash Buying (Spot Purchase)

When you buy AbbVie stock “for cash,” you are purchasing real shares of AbbVie Inc. on the New York Stock Exchange, directly owning a piece of the company. This approach typically involves a fixed commission per order—Canadian online brokers usually charge between CAD $5 and $10 per trade.

Example

Suppose AbbVie shares are trading at $193.05 USD. With a $1,000 CAD investment (approx. $725 USD at current exchange rates), and accounting for a CAD $5 commission, you could buy approximately 3 shares of AbbVie.
- Gain Scenario:
If AbbVie’s share price rises by 10%, your holdings would be worth approximately $1,100 CAD gross.
Result: That’s a +$100 gain, or +10% on your investment (not including foreign exchange fluctuations or taxes).

Trading via CFD

CFD (Contract for Difference) trading allows you to speculate on AbbVie’s price movements without actually owning the shares. With CFDs, brokers make their profit primarily from spreads (the difference between the buy and sell price) and overnight financing costs if you hold positions for more than a day. CFD platforms often let you use leverage—magnifying gains as well as losses.

Example

You open a CFD position on AbbVie with $1,000 CAD (around $725 USD) and choose 5x leverage, giving you market exposure of approximately $5,000 CAD ($3,625 USD).
- Gain Scenario:
If AbbVie’s price climbs by 8%, your leveraged position delivers an 8% × 5 = 40% return.
Result: That’s a +$400 gain on a $1,000 outlay (excluding spreads and overnight financing fees).

Final Advice

Before investing, it’s important to compare brokers’ fees, available platforms, and specific conditions—including commissions, spreads, access to U.S. stocks, and currency conversion rates. Your choice between buying AbbVie shares directly or trading via CFDs should depend on your investment goals and risk tolerance. For more information on trusted Canadian brokers and up-to-date fee comparisons, you can consult our broker comparator further down the page.

Platforms

Minimum Deposit

Discover

#1

Tier 1 regulation, including ASIC and FSA

#1Recommended Offer

Star Trader

4.9

Minimum Deposit

$50

Discover

with our partner Star Trader

#2

Broker specializing in Forex and CFDs

#2

IFC Markets

4.8

Minimum Deposit

$1

Discover

with our partner IFC Markets

#3

Broker regulated since 2006

#3

Avatrade

4.8

Minimum Deposit

$100

Discover

with our partner Avatrade

Our 7 tips for buying AbbVie stock

The latest news about AbbVie

AbbVie delivered robust Q1 2025 financial results, highlighted by double-digit revenue growth in immunology and neuroscience. Total revenues reached $13.34 billion, representing an 8.4% year-over-year gain, while adjusted EPS climbed 6.5% to $2.46. The report, released April 25, underscores the enduring demand for blockbuster drugs Skyrizi and Rinvoq, which both notched revenue increases above 50%. AbbVie’s performance is especially relevant to Canadian institutional investors and portfolio managers due to the company’s significance in both global healthcare indices and North American dividend portfolios, as well as the widespread prescription of its innovative therapies in Canada through provincial healthcare systems and private insurers.

AbbVie increased its full-year 2025 adjusted diluted EPS guidance, signaling management’s confidence in sustained earnings momentum. The revised outlook now projects adjusted EPS of $12.09 to $12.29, up from the prior $11.99 to $12.19, offering reassurance for income-oriented Canadian investors seeking reliable dividend growers amid ongoing market volatility. This upward adjustment is notable in the current macroeconomic environment and suggests that the company’s diversified product mix is effectively mitigating the decline in Humira, formerly its largest revenue contributor and a significant product in the Canadian pharmaceutical landscape.

Recent regulatory approvals and pipeline progress strengthen AbbVie's medium-term growth profile and product offering in Canada. Notably, the recent European Commission approval for Rinvoq’s new indication and the FDA authorization of Emblaveo highlight the momentum of AbbVie’s R&D engine. With regulatory harmonization between Canada and these jurisdictions, such milestones often serve as precursors to Health Canada submissions and future product introductions, paving the way for expanded therapeutic options for Canadian healthcare providers and patients, and providing catalysts for local revenue growth.

Technical analysis shows AbbVie stock maintains strong bullish momentum, with prices consistently above major moving averages. Key technical indicators remain constructive: the stock trades firmly above the 20, 50, 100, and 200-day moving averages, MACD continues to print a bullish reading, and RSI is in a neutral range. For Canadian investors and institutions with exposure via U.S.-listed shares or ETFs, this technical strength—despite a recent pullback—supports confidence in the share’s stability. The company’s relatively low beta (0.54) may also be especially attractive for Canadian investors seeking resilience versus broader market swings.

AbbVie’s strategic partnerships and active licensing demonstrate long-term commitment to innovation and international market integration, which benefits Canadian stakeholders. Recent collaborations with Xilio Therapeutics and Gubra, focused on next-generation immunotherapies and obesity treatments respectively, position the company to capture emerging market opportunities relevant to Canada’s health priorities, including chronic disease management. Coupled with its consistent dividend policy—which remains attractive even after accounting for cross-border withholding tax—AbbVie stands out as a vital healthcare investment option for Canadian funds, portfolio managers, and retail investors prioritizing stability, growth, and global exposure.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.